Supernus Pharmaceuticals (SUPN) has provided an announcement.
Supernus Pharmaceuticals has increased the base salaries and awarded bonuses and stock options to its top executives, with President and CEO Jack A. Khattar receiving a salary bump to $1,001,500 and bonuses and stock options tied to performance goals. The raises, effective January 1, 2024, align with industry standards and were guided by independent compensation consultants. Stock options will vest over four years, with their exercise price set at the stock’s closing price on the date of grant approval, while performance share units (PSUs) will vest upon achieving set performance targets.
Learn more about SUPN stock on TipRanks’ Stock Analysis page.
